Precision Medicine News and Research

RSS

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

Study supports future possibility of personalized medicine for cervical cancer

Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.

1 Jun 2013

New Translational Proteomics journal launched by Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of Translational Proteomics, an online-only, open access journal devoted to transferring fundamental discoveries in the field of proteomics to clinical applications, accelerating understanding and treatment of human diseases.

28 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

Mayo Clinic, Cancer Genetics form joint venture to improve cancer care

Mayo Clinic and Cancer Genetics Inc. today launched OncoSpire Genomics, a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

GfK to deliver major presentation on personalized medicine at PBIRG Annual General Meeting

GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.

17 May 2013

Weekend reading: Volunteers in the battle with heart disease; Psychiatry without medication; Owning your genes

Psychiatrists who take time with their patients are not the norm. It's not because others don't care. Rather the system rewards efficiency, not empathy.

17 May 2013

Angelina Jolie's choice underscores screening and treatment costs

News outlets report on the cost of and questions surrounding Angelina Jolie's decision to have genetic testing and then to undergo a double mastectomy as preventive surgery.

16 May 2013

Researchers identify clue to explain the reversible memory loss caused by statins

The U.S. Food and Drug Administration and physicians continue to document that some patients experience fuzzy thinking and memory loss while taking statins, a class of global top-selling cholesterol-lowering drugs.

13 May 2013

ALS-ETF, Denovo partner to explore personalized medicine approach for ALS

The ALS Emergency Treatment Fund and Denovo Biomarkers have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.

10 May 2013

New research from Wake Forest Baptist looks at gene expression profiling in breast cancer

Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most deadly types of breast cancer.

10 May 2013

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.

9 May 2013

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcome of a prostate biopsy.

9 May 2013

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.

8 May 2013

Expert to explain how drugs induce damage to DNA in public lecture on May 16

Anticancer drugs save lives and/or improve the quality of life for many cancer patients. Many anti-cancer drugs work by killing tumor cells after inducing damage to DNA.

4 May 2013

Cancer Genetics introduces proprietary urogenital cancer array for diagnosing kidney cancer

Cancer Genetics, Inc., a leader in oncology-focused personalized medicine, has launched a proprietary urogenital cancer array, UroGenRA, intended for kidney cancer diagnosis and subtyping in its own laboratory.

3 May 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

Oregon Health & Science University and Intel Corp. are teaming up to develop next-generation computing technologies that advance the field of personalized medicine by dramatically increasing the speed, precision and cost-effectiveness of analyzing a patient's individual genetic profile.